Living longer with HIV: What does it mean for cancer risk?

Current Opinion in HIV and AIDS

Volumn 4, Issue 1, 2009, Pages 1-2

  Grulich, Andrew E ^a  

^a UNIVERSITY OF NEW SOUTH WALES   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT;

CANCER INCIDENCE; CANCER RISK; CD4 LYMPHOCYTE COUNT; CONDYLOMA ACUMINATUM; EPSTEIN BARR VIRUS; HEAD AND NECK CANCER; HERPES VIRUS INFECTION; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HODGKIN DISEASE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; KAPOSI SARCOMA; LIFESPAN; NONHODGKIN LYMPHOMA; PRIORITY JOURNAL; SHORT SURVEY;

ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CD4 LYMPHOCYTE COUNT; HIV INFECTIONS; HUMANS; LIFE EXPECTANCY; NEOPLASMS; RISK FACTORS;

EID: 67849132134     PISSN: 1746630X     EISSN: 17466318     Source Type: Journal    
DOI: 10.1097/COH.0b013e32831c508a     Document Type: Short Survey

References (13)

1. Antiretroviral Therapy Cohort Collaboration. Life expectancy of individuals on combination antiretroviral therapy in high-income countries: a collaborative analysis of 14 cohort studies. Lancet 2008; 372:293-299.
2. Lewden C, May T, Rosenthal E, et al. Changes in causes of death among adults infected by HIV between 2000 and 2005: the 'Mortalite 2000 and 2005' surveys (ANRS EN19 and Mortavic). J Acquir Immune Defic Syndr 2008; 48:590-598.
3. Palella FJ Jr, Baker RK, Moorman AC, et al. Mortality in the highly active antiretroviral therapy era: changing causes of death and disease in the HIV outpatient study. J Acquir Immune Defic Syndr 2006; 43:27-34. (Pubitemid 44306484)
4. Cooper DA. Life and death in the cART era. Lancet 2008; 372:266-267.
5. El-Sadr WM, Lundgren JD, Neaton JD, et al. CD4+ count-guided interruption of antiretroviral treatment. N Engl J Med 2006; 355:2283-2296. (Pubitemid 44837777)
6. Goedert JJ, Cote TR, Virgo P, et al. Spectrum of AIDS-associated malignant disorders. Lancet 1998; 351:1833-1839.
7. Grulich AE, van Leeuwen MT, Falster MO, Vajdic CM. Incidence of cancers in people with HIV/AIDS compared with immunosuppressed transplant recipients: a meta-analysis. Lancet 2007; 370:59-67.
8. Patel P, Hanson DL, Sullivan PS, et al. Incidence of types of cancer among HIV-infected persons compared with the general population in the United States, 1992-2003. Ann Intern Med 2008; 148:728-736.
9. Franceschi S,Maso LD, RickenbachM, et al. Kaposi sarcoma incidence in the Swiss HIV Cohort Study before and after highly active antiretroviral therapy. Br J Cancer 2008; 99:800-804.
10. Polesel J, CliffordGM, Rickenbach M, et al. Non-hodgkin lymphoma incidence in the Swiss HIV Cohort Study before and after highly active antiretroviral therapy. AIDS 2008; 22:301-306.
11. Baker JV, Peng G, Rapkin J, et al. CD4+ count and risk of non-AIDS diseases following initial treatment for HIV infection. AIDS 2008; 22:841-848. (Pubitemid 351563833)
12. International Collaboration on HIV and Cancer. Highly active antiretroviral therapy and incidence of cancer in human immunodeficiency virus-infected adults. J Natl Cancer Inst 2000; 92:1823-1830.
13. Biggar RJ, Jaffe ES, Goedert JJ, et al. Hodgkin lymphoma and immunodefi- ciency in persons with HIV/AIDS. Blood 2006; 108:3786-3791.